Ads
related to: merck
Search results
...Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion...
Benzinga via Yahoo Finance· 4 hours agoOn Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock...
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Zacks via Yahoo Finance· 1 day agoMerck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a...
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 2 days agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Summit Shares Soar After Cancer Drug Tops Merck’s Keytruda
Bloomberg via Yahoo Finance· 23 hours ago(Bloomberg) -- Summit Therapeutics Inc. shares jumped after the biotech company said a late-stage...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 7 hours agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
Summit Therapeutics’ stock surges as lung-cancer treatment vies with Merck’s blockbuster
Market Watch· 24 hours agojumped more than 270% Thursday after the company said its experimental cancer drug outperformed ...
Merck to Acquire EyeBio
Morningstar· 2 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today ...
Germany's Merck, Korean science institute set up R&D partnership
dpa international via Yahoo News· 1 day agoGerman science and technology major Merck and the Korea Advanced Institute of Science and Technology...
Competitor to Merck's Keytruda Worries Some Investors
Barrons.com· 1 day agoInvestors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming...
Is Merck & Co., Inc.'s (NYSE:MRK) Recent Performance Underpinned By Weak Financials?
Simply Wall St. via Yahoo Finance· 3 days agoMerck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could...